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ABSTRACT

Investigating Potential Bioactive Compounds from Rhodococcus and Their Effects on MCF7
Breast Cancer Cells
by
Megan Crabtree

Many drugs used in the treatment of various cancers are derived from or influenced by
compounds from nature. The soil bacterium Rhodococcus is of interest because of its identified
secondary metabolic pathways and the production of novel natural antibiotics from several
strains. In this study a solid agar extraction method was used to collect compounds from
strains of Rhodococcus. These bacterial compound extracts were then tested using a MTT assay
in order to evaluate their effectiveness in augmenting MCF7 breast cancer cell death. The
results of two way ANOVA analyses revealed 18 compound extracts from 15 strains of
Rhodococcus that showed significant p-values when assayed with MCF7 breast cancer cells but
nonsignificant interaction p-values when assayed with the healthy cell control. These results
prompt further identification of specific compounds present in the bacterial extract that caused
cell death as well as a mechanism of interaction with the breast cancer cells.
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CHAPTER 1
INTRODUCTION
Cancer at a Glance
In recent years cancer has ranked number 2 among the leading causes of death in the
United States. It is estimated that in 2012 alone there were 577,000 deaths from this disease
along with 1.6 million new cases of cancer diagnosed in the United States. The occurrence of
this disease in both men and women across the racial divides makes it a cause for concern in
the global community. Improvements in cancer treatments across the spectrum of cancers have
aided in increasing the 5-year survival rate from 49% to 67% over a 30-year period (American
Cancer Society, 2012). Improvements in cancer treatments not only stem from a more in-depth
understanding of cancer cell behavior at the cellular level and organismal level but also from
improved treatment technologies.
Today breast cancer is the most frequently diagnosed cancer among women and ranks
second in the leading cause of cancer death in this gender (American Cancer Society, 2012).
Depending on factors such as cancer cell characteristics, size, stage, and patient preference, the
current treatments for breast cancer include lumpectomy, mastectomy, hormone therapy, and
a combination of radiation and chemotherapy drugs. These treatments have increased the 10year survival rate of breast cancer patients to 83% (American Cancer Society, 2012). While it
has been demonstrated that the current treatment plans that involve chemotherapy drugs are
effective, these chemicals are often physically taxing to the patient and damaging to the
healthy tissues of the body. The compounds that have emerged from nature have been shown
to be successful in the treatment of many diseases and conditions without all of the side effects
9

that are associated with traditional pharmaceuticals. A more in depth look into compounds
isolated from nature could be the key to more specific and successful treatment of cancer that
is less taxing to the body.
History of Cancer Treatment
Many drugs used today to treat a wide variety of human diseases and conditions are
derived from compounds that have been isolated from nature. In the past 20 years there have
been great strides seen in the area of biotechnology. This has given scientists the ability to
synthesize compounds. This opportunity has shifted the focus from isolating natural products to
creating synthetic compounds in hopes of designing more efficient drugs. This shift brought
great hope and possibilities in the beginning stages of its exploration; however, there has not
been the large increase in drug productivity that was first hoped.
A 25-year study investigated the trend in the production of new active substances
(NASs), also referred to as New Chemical Entities (NCEs). Initially there was a sharp increase in
the number of synthesized drugs that had been approved for clinical testing. As time
progressed it was seen that the number of synthesized drugs approved for clinical trials had
decreased by a large margin (Newman and Cragg 2007). This same 25-year study evaluated all
the drugs used for the treatment of all diseases in every country from every source. It was
found that only 30% could be classified as purely synthetic in origin. The other 70% of the
drugs examined where either a natural product or had some basis in a natural product such as a
natural mimic, nature derived pharmacophore, or natural product with a synthetic modification
(Newman and Cragg 2007). With all of the advancements in synthesis technology as well as a
10

better understanding on how chemical entities impact the cell under disease conditions, a large
number of successful chemical products still have a natural basis. In this same study by
Newman and Cragg, a closer look was given to those drugs on the market that are specifically
anticancer. Out of the 175 drugs in this category that are available to Japan and the Western
World, only 24% can be classified as purely synthetic. The other 76% of the anticancer drugs are
natural products or have some natural product influence (Newman and Cragg 2007). These
percentages demonstrate the vast influence that nature has on providing effective compounds
to help treat a wide range of diseases and has led many scientists to reconsider the exploration
of natural products (Zhu et al. 2011).

Natural Compounds Inhibiting the mTOR Pathway
Depending on the cancer cell type and stage of progression, cancerous cells can present
one or multiple types of mutations. These mutations can occur in regulatory pathways and lead
to uncontrolled proliferation, angiogenesis, and evasion of cell death, which is a modification of
the cellular response that promotes cell survival instead of cell death when the cell receives
stress stimuli. Recently scientists have explored the use of kinase inhibitors to correct or bypass
the mutations in regulatory pathways. Kinases are enzymes responsible for adding a phosphate
group to another protein. This can cause the phosphorylated protein to undergo a
conformational change. This conformational change can result in activation of an enzyme or
series of enzymes within a pathway that promote essential cell processes such as metabolism,
protein synthesis, and proliferation.
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An important regulator within the cell is mTOR, a serine/threonine kinase. This protein
is responsible for regulating cell functions such as cell growth, transcription, translation,
metabolism, energy balance, and cell survival. It works by acting on signals carrying information
such as nutrient levels, hormones, various growth factors, and other cell stresses and activating
or inhibiting the appropriate downstream pathways (Watanabe et al. 2011). For example, a
receptor on the surface of the cell binds to a growth factor and activates a signaling cascade.
This signal gets passed through a series of enzymes to mTOR. From here mTOR is responsible
for phosphorylating transcription factors and translational regulators that promote cell growth
and survival while at the same time inhibiting enzymes that would result in cell death.
Given its important role in regulating cell death and cell survival, the mTOR pathway has
been a target of some recent anticancer drugs with varying amounts of success. Sirolimus, also
known as rapamycin is a kinase inhibitor that is derived from a soil sample collected from Ester
Island, Rapa Nui. It was identified as a macrolide antibiotic produced by the bacterium
Streptomyces hygroscopicus (Vezina et al. 1975). Upon discovery and extraction using organic
solvents, rapamycin was initially used as an antifungal against Candida albicans, Cryptococcus
neoformans, and Aspergillus fumigatus. These fungi can cause oral and genital infections, fungal
meningitis, and invasive lung infections in patients who have suppressed immune systems
(Vignot et al. 2004). Rapamycin is currently used as an immunosuppressant in patients who
undergo organ transplantation because of its effectiveness in prohibiting T-lymphocyte
activation and proliferation.
Along with immunosuppressive properties, it was also discovered that rapamycin
displayed antiproliferative characteristics. The National Institutes of Cancer (NIC) screened 60
12

tumor cell lines and found that there was rapamycin sensitivity in doses under 2000 ng/ml in
leukemia, ovarian, breast, central nervous system, and small cell lung cancer cell lines (Vignot et
al. 2004). After success in clinical trials, Rapamycin was approved in 1999 by the FDA for use in
anticancer treatment (Zhu et al. 2011). Investigations continue in creating different analogues
of rapamycin to more specifically target different types of cancer based on their defining
characteristics and behaviors. Two successful analogues of rapamycin currently on the market
are Everolimus and Temsirolimus, which are both used to impede the growth and spread of
advanced renal cell carcinoma in cases of tumor resistance to other anticancer drugs. Both of
these drugs have been successful in extending the survival of the patient for a number of
months to years (Zhu et al. 2011).
In recent years scientists have taken a closer look at the effects that rapamycin has on
breast cancer. In this study breast cancer cell lines MDA-MB-231, T47D, MCF-7, and SK-BR3
were examined. These cell lines were selected based on different cell characteristics (Table 1).

Table 1: Breast cancer cell lines and their receptor characteristics. ER-Estrogen receptor. erbB2an epidermal growth factor receptor.
Cell Line
Characteristics
Rapamycin Sensitivity
MDA-MB-231
T47D

ER-Negative
Does not overexpress erbB2
ER-Positive

yes

MCF-7

ER-Positive

yes

SKBR3

ER- Negative
erbB2-overexpressing

yes

13

no

It was found that the cell lines T47D, MCF-7, and SKBR3 showed sensitivity to rapamycin
while MDA-MB-231 showed resistance (Table 1). This study gave insight into the type of cell
profile or receptors that need to be present in order for rapamycin to be effective in halting
cancer progression (Chang et al. 2004).

The Use of Steroids in Anticancer Treatment
Steroids are characterized by their origin and their chemical structure. They are fat
soluble molecules that originate from a plant or animal source and have a steroid nucleus that
contains three 6-member carbon rings and one 5-member carbon ring. The human body has
the ability to synthesize and secrete steroids into the bloodstream. These are referred to as
steroid hormones and are responsible for regulating bodily functions that include the
antiinflammatory response, sexual maturation, and fetal development during pregnancy.
Through a multistep process called sterodogenesis, cholesterol is converted to progestins, then
to androgens, and lastly into estrogens. The regulation of this process is essential in ensuring
the body has a correct response to stimuli (Gupta et al. 2013).
Some cancer cell types have been shown to be stimulated by certain steroid hormones.
Estrogen has proven to be a major player in promoting proliferation in some hormone sensitive
breast, uterine, ovarian, prostate, and endometrial cancers (Gupta et al. 2013). Estrogen
receptors in breast tissue are located on the cellular membrane and in the cytoplasm. These
receptors have 2 isoforms, ERα and ERβ. Both isoforms are ligand-regulated transcription
factors that transmit hormone signals to cause various responses in the cell. In normal breast
tissue, ERα and ERβ bind estradiol causing a signaling cascade that controls proliferation and
14

differentiation of the cell. These 2 isoforms are present at equally low levels in normal breast
tissue; however, in some type of breast cancer ERα is overexpressed. This overexpression
stimulates the hormone sensitive cells to excessively proliferate in response to estrogen (Renoir
et al. 2013). Estrogens have a direct effect on cell proliferation in certain hormone sensitive
cancers. This has prompted researchers to focus their treatment efforts on disrupting
steroidogenesis with aromatase inhibitors and disrupting the ability for estrogen to bind to its
receptors. Some successful steroid drugs on the market have a natural origin or natural
influence. Further exploration of sources of steroid production such as Rhodococcus could
provide even more success in this cancer treatment approach (Renoir et al. 2013).
For their use as anticancer agents, steroids have been chemically modified to act as
cytotoxic and cytostatic agents. The use of antiestrogens, a cytostatic approach in hormone
sensitive breast cancer, has shown some success in arresting tumor development.
Antiestrogens compete with endogenous estrogens for binding with estrogen receptors. When
the antiestrogen binds to the receptor, it does not initiate the signaling cascade that eventually
leads to cell proliferation. This prevents the estrogen sensitive breast cancer cells from dividing
in the presence of estrogen (Gupta et al. 2013).
Antiestrogens became an area of interest following the initial success of tamoxifen for
treating breast cancer. Tamoxifen emerged as a treatment in the early 1970s and still remains
an effective choice for treating receptor positive breast cancer in women who are both
premenopausal and postmenopausal. This synthetic drug works through a competitive inhibitor
method where it binds in the place of estrogen and does not stimulate cellular growth. While
this drug has proven successful, resistance is always a factor when dealing with an endocrine
15

treatment. There has been resistance to the tamoxifen in later stages of breast cancer as well
as in breast cancers that overexpress the ErbB-2 gene, which makes up 15%-20% of all breast
cancers diagnosed (Clemons et al. 2002).
To combat cancer cell drug resistance further research has been conducted to
investigate the binding pocket of the estrogen receptors. In understanding the structure of the
receptor, a more specified competitive inhibitor can be designed. It was seen that a
modification at position 7α or 11β is effective in promoting antiestrogenic activity. This led to
the discovery of nine potential steroidal estrogens, all of which have shown success and
promise in clinical trials (Table 2).
Table 2: Modified steroids that have shown potential as an antiestrogen
treatment in breast cancer cells that are hormone sensitive (Gupta, Kumar,
and Negi, 2013).
1.
2.
3.
4.
5.
6.
7.
8.
9.

SR16137 (153)
SR16234 (154)
RU3941 (155) 11β-Amidoalkoxyphenyl estradiol (159)
RU51625 (156)
ICI 164,384 (157)
11β-Perfluorenated fulvestrant (158)
11β-Amidoalkoxyphenyl estradiol (159)
11β-(4-Pentafluorinated alkylsulphonylpentayloxyphenyl estradiol (160)
Fulvestrant (161)

Fulvestrant (161), marketed under the name “Faslodex”, is currently in clinical use
against breast cancers that are resistant to tamoxifen. To date it remains the only steroidal
antiestrogen that down regulates ERα and does not have estrogenic activity. This means that it
does not mimic or block the actions of naturally occurring estrogen in the body. Fulvestrtant
works by binding to the estrogen receptors and inhibiting the receptors from dimerizing and
becoming active transcription factors. In addition to deactivation, the binding of fulvestrant to
16

the estrogen receptors speeds up the degradation of the estrogen receptors thus decreasing
the number of them in the cell. In this case tumor cells that are estrogen dependent and thrive
by using estrogen as a growth factor die off because they are not getting the excess amount of
growth signaling that promotes cell division and growth. This competitive binding does not
cause all of the estrogen receptors to undergo degredation, thus allowing the naturally
occurring estrogen to function on the remaining receptors in the cell. The other promising
steroidal antiestrogens are SR 16137 (153) and SR 16234 (154), which act as a competitive
inhibitor similar to tamoxifen (Gupta et al. 2013).

Polar Compounds as Anticancer Agents
Histones play a large role in gene expression in the cell. Histone acetylation by histone
acetyltransferases (HAT) cause the condensed chromatin to relax. When the DNA is relaxed, it
provides the opportunity for the exposed genes to be transcribed. The reverse process, histone
deacetylation by histone deacetylases (HDAC), removes the acetyl group from the histone and
causes DNA condensation. This is a highly regulated process and disruption of HAT and HDAC is
associated with cancer (Schmudde et al. 2010).
It is understood that in addition to genetic mutations epi-genetic changes to the
regulation of HAT and HDAC can alter cell phenotype. Regulation of gene expression has been
introduced as another method of cancer treatment. HDAC inhibitors (HDIs) are molecules that
interfere with the function of histone deacetlyase (Richon 2006; Richon et al. 2009). They work
by binding to the catalytic domain of histone deacetlyase and preventing it from removing the
acetyl group from the histone protein. This leaves the DNA in a relaxed state and more
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transcriptionally active (Schmudde et al. 2010). By altering the transcription of about 22% of
genes, HDIs have shown to be effective in causing cell cycle arrest, terminal differentiation, or
apoptosis in transformed cells.
After small polar molecule screens in the 1970s through 1990s, several molecules
emmerged from screens of bishydroxamic acids that showed inhibitory potential. These
molecules lead to the development of vorinostat (also known as suberoylanilide hydroxamic
acid or SAHA). Vorinostat is a synthetic, second generation polar-planar compound. It is a
potent HDI and acts by biding to the catalytic domain of the histone deacetylase. In addition
vorinostat increases the acetylation of nonhistone related transcription factors such as p53,
HIF-1α, and EF2 and also acetylation of cytoplasmic proteins α-tubulin, cortactin, and HSP90
(Richon et al. 2009). This change in acetylation pattern in the cell has been shown to induce
differentiation, arrest cell growth, and induce apoptosis in transformed cells at a low dose that
does not prove to be toxic to normal cells (Richon 2006). It was approved by the US Food and
Drug Administration for the treatment of cutaneous T cell lymphoma in October 2006 (Hymes,
2010; Schmudde et al. 2010).

Nature Derived Histone Deacetylase Inhibitor
The only other approved HDI currently on the market for treatment of T cell lymphoma
is romidepsin (Lu et al. 2012). This drug got FDA approval in November 2009 and also goes by
the name Istodax. Romidepsin is a cyclic peptide antibiotic that was isolated from the
bacterium Chromobacterium violaceum. Similar to vorinostat, romidepsin inhibits histone
deacetylase and alters gene expression in the cell. This has been shown to not only increase
18

histone acetylation but also increase p21 and cyclin E and decrease Cyclin D1, which leads to
cell cycle arrest at both the G1 and G2/M phases (Hymes, 2010).
Romidepsin and its success in treating T cell lymphoma has promoted further
exploration as to its effect on other cancers. In preclinical models, romidepsin has been shown
to induce apoptosis of lung, breast, and melanoma cancers. (Hymes, 2010). Combination
studies with romidepsin and cisplatin have shown promise in clinical trials by causing DNA
damage induced apoptosis in ovarian cancer (Wilson et al. 2012). This drug is also in phase II
clinical trials with patients who have recurrent or metastatic head and neck cancer and has
shown mild success in stopping tumor progression (Haigentz et al. 2012).

Bioactive Compounds from Bacterial Families
In an expansive phylogenetic study the origins of many successful and commonly used
natural drug-like structures were analyzed. From this study the top 10 phylogenic families that
have produced the highest number of drugs approved or currently in clinical trials were
identified. The family Actinomycetales contains 9 genera that have been known to produce
compounds with drug activity (Zhu et al. 2011). Presently, these 9 genera have been studied
and shown to be successful at producing drug-like compounds; however, there has been little
focus on the other species within this family and their role in creating drug-like compounds.
Close examination of the structure of the nature-derived approved and clinical trial drugs in use
today reveals that they are composed of several dozen molecular scaffolds, or core structures.
These molecular scaffolds are created by enzymes that are partly encoded in specific secondary
metabolite gene clusters in a selected group of species. It is not known if these bioactive
19

compounds are present within select species or scattered within the phylogenetic tree;
however, evidence from the drug productive families to date suggests that they are clustered
(Zhu et al. 2011). Exploring species that are closely related to species that are known to
produce useful compounds may be a good strategy of bioprospecting. This strategy may reveal
new natural product compounds that could potentially be of great importance to the medical
community.
In looking at the bacterial phylogenetic tree for the order Actinomycetales, the family
Nocardiaceae, which includes Rhodococcus, is related to the family Corynebacteriaceae. In
2000 the family Corynebacteriaceae was identified as a drug-producing family. Due to this
discovery it has quickly become an focus of bioprospecting research (Zhu et al. 2011). Given the
observation that drug producing families tend to cluster in the phylogenetic tree rather that
scatter, the family Nocardiaceae, more specifically the genus Rhodococcus, would be a good
area of focus in hopes of investigating potential bioactive compounds.
The Genus Rhodococcus
The bacterium Rhodococcus, a genus of aerobic, gram positive bacteria, is a member of
the order Actinomycetales. This genus displays a wide range of different phenotypes and
inhabits many environments. It has been isolated from a variety of locations including sea level
and Alpine soils and deep sea and coastal sediments (de Carvalho et al. 2005). This order, which
has shown great success in producing drug-like products, includes Streptomyces, a major
antibiotic producer widely used in medicine today (McLeod et al. 2006). Rhodococcus is best
known for its impact on industry in the areas of fossil fuel desulfurization and the production of
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acrylamide and acrylic acid. Rhodoccucus is also known for bioactive steroid production, which
makes it a target for further exploration in its use in a medical setting.
Genome Sequencing of Rhodococcus
A better understanding of the genus Rhodococcus came to light when the genome of
strain RHA1 was sequenced and examined (McLeod et al. 2006). RHA1 is a strain of
Rhodococcus that has been isolated from soil and is best known for its ability to break down
polychlorinated biphenyls (PCBs). This strain is also noted for its ability to use aromatic
compounds for its source of carbon. The genome consists of 9,702,737 base pairs compiling 4
linear DNAs, 1 chomosome and 3 plasmids. It has also been observed that the DNA contains a
high percentage of guanine and cytosine content.
Sequencing of this strain revealed that Rhodococcus has a diverse secondary
metabolism. This discovery has led to bioactive compound discovery, thus opening the door to
the potential of this bacterium to influence other areas of science. In examining the genome it
was discovered that RHA1 contains 9,145 predicted protein coding sequences. Based on current
knowledge 38.4% of these sequences encode proteins of unknown function (McLeod et al.
2006). When the secondary metabolism of RHA1 was investigated, it was found that the
genome encodes for 24 nonribosomal peptide synthatases and 7 polyketide synthases. Other
Actinomycetes also possess these secondary metabolic genes, all of which are involved in cell
signaling, pigment production, siderophores, and antibiotic production. This finding of a
relatively large number of potential secondary metabolic genes is of interest because no
rhodococcal secondary metabolites had been reported up to this point (McLeod et al. 2006).
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Upon further investigation of the genome, it was discovered that RHA1 contains an oppencoded oligopeptide transporter, which is a known regulator of secondary metabolic genes
(McLeod et al. 2006). These unidentified synthases and transporters show promise in
uncovering more applications for this genus of bacteria.
Bioactivity from Compounds Isolated from Rhodococcus
Until the published work of McLeod, Rhodococcus was not widely investigated for the
potential production of secondary metabolites. Shortly after the complete sequencing of the
RHA1 genome, an in-depth look at the genome resulted in the discovery of 2 antimicrobial
peptides from Rhodococcus josti K01-B0171. These compounds were isolated from a soil
sample taken from Yunnan Province, China. Two cyclic peptide structures demonstrated a
lariate or “lasso” type structure and were named lariatins A and B. Both Lariatin A and B were
unable to inhibit the growth of Gram negative strains; however, they were both able to inhibit
the growth of Gram positive Mycobacterium smegmatis. In addition it was found that lariatin A
was able to inhibit the growth of Mycobacterium tuberculosis (Iwatsuki et al. 2007).
A lab in Japan isolated and identified a new antibiotic from a strain of Rhodococcus.
Aurachin RE that emerged from the strain R. erythropolis JCM 6824. It is a quinolone antibiotic
that has a similar structure to aurachin C antibiotics that had previously been identified from
Stigmatella aurantiaca. Compared to aurachin C, aurachin RE has a wider scope of antibiotic
activity against Gram positive activity (Kitagawa and Tamura 2008).
Further investigation was done in a lab in Florida focusing on the potential of
Rhodococcus. The investigation involved horizontal gene transfer and the production of
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antibiotics by Rhodococcus. In this study Rhodococcus was cocultured with Streptomycete
padanus, which is known to produce the antibiotic actinomycin. This coculturing resulted in the
production of 2 antibiotics, Rhodostreptomycin A and Rhodostreptomycin B by the strain of
Rhodococcus. These results indicate that gene transfer occurred between these 2 cocultured
bacteria that resulted in the production of a new antibiotic (Kurosawa et al. 2008).
Rhodococcus in the Medical Setting
It is already known that Rhodococci have an exceptional ability to degrade hydrophobic
natural compounds as seen by their success in the area of fossil fuel desulfurization. This
success can be because their large genome size and the typical appearance of large linear and
circular plasmids allow for the presence of many catabolic enzymes and secondary metabolites
(Ludmila et al. 2009). Rhodococci produce oxygenases, enzymes that are able to oxidize
compounds. However, the potential of secondary metabolic compounds has not been explored
for their use in a medical setting.
Present Work
In the present study we examine the cytotoxicity of polar compounds that have been
extracted from various strains of Rhodococcus on the MCF7 breast cancer cell line. The
cytotoxicity, or the loss of viability of a cancer cell by an external source was determined using
an MTT assay. Based on the phylogeny of the genus Rhodococcus and its relation to other drugproducing families in the order Actinomycetales, we hypothesize that Rhodococcus may
produce compounds that will show activity against the MCF7 breast cancer cell line.
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CHAPTER 2
MATERIALS AND METHODS

Bacterial Strains
Sixty isolated strains of Rhodococcus were used in this study. These bacterial isolates
were cultivated from soil samples from multiple sites in Eastern Tennessee as well as several
sites abroad (Table 3). Each strain was purified and catalogued by previous graduate students
Tom Barber (Barber 2010) and Ralitsa Borisova (Borisova 2011).
Table 3: Isolated bacterial strains from the genus Rhodococcus collected and purified from
various soil samples.
WFDE08

NPDEM14

NPDE012

CODE08

MTDE09

WFDEM2

WLDET3

CBRMT10

MTM306

MTM3W5.2

NP3T8.1

APDE02

NFDEM13

KCHXC3

MTM3T17

WFDEM3

MTM3W13

NPM311

MTM3W12.1a

CBM3T2

CBM3W9

CBRMT7

MTM310

MTM3T5

BTHXC2

MTM304

CODET15

EMHX01

A2M306

BTHXC10

CBM3T2

ACM3C8

ACM3W1

BTHXC8

DSM301

AZM3R1

NPDE011

CODET15

WLDE08

WDM310A

BTHXC10

WDM3P2

ACM3C1

WFIEW1

WFDEM6

SCM3011

MTM3015

WFDEM6

ACM3W7

MTM309a

ACM3W7

WDM318

MTM304

MTM3T20

CBRMT7

ACM3W5

NPM311

WDM310a

WDEW

MTDE09
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Growth Conditions
All strains were grown using Rich Media (RM) broth and agar. RM was prepared using
the following components:
Rich Media (RM) agar
1) Distilled H2O

500 milliliters(mL)

2) Dextrose

5 grams(g)

3) Nutrient Broth

4g

4) Yeast Extract

0.25 g

5) Bacto Agar

7.5 g

Rich Media (RM) broth
1) Distilled H2O

500 milliliters(mL)

2) Dextrose

5 grams(g)

3) Nutrient Broth

4g

4) Yeast Extract

0.25 g

For agar media 30ml of the autoclaved RM was poured into 100 mm petri dishes. The
agar was allowed to cool and solidify at room temperature followed by storage at 4°C until use.
For RM broth media 100ml of the autoclaved broth was transferred into five 150ml sterile
bottles and stored at room temperature until use.
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Seed Cultures and Agar Plates
Seed cultures of each strain were prepared and used for inoculation of agar plates for
compound extraction. A small amount of bacterial culture for each strain was taken from RM
storage slants using a sterile loop. The bacteria were placed in a test tube containing 2.5 mL of
RM broth. Each tube was placed in a water bath at 30°C for 24 hours or until the broth reached
an appropriate level of turbidity to indicate bacterial growth.
The bacteria grown in the broth was then used to inoculate the agar plates. For each
strain 100µL of the seed culture was transferred to a 100mm diameter RM agar plate and
spread over the entire surface of the agar using a sterile cotton swab. Each plate was then
wrapped in parafilm to prevent desiccation and left to grow at room temperature on the
laboratory bench top for 2-4 weeks.
Compound Agar Extraction
An agar extraction method was used to collect any polar compounds that were being
made and released by the soil isolates (derived from Carr, 2010). After growth for 2-4 weeks,
each agar plate was divided in half. Each half was placed into a 100mL beaker and the agar was
chopped into small pieces. Two beakers for each strain underwent extraction; one with 100%
methanol and the other with 100% ethyl acetate. In each case 50mL of the solvent was added
to the designated beaker with the chopped up agar and left covered for 24 hours in a fume
hood. After soaking for 24 hours, the methanol extract and the ethyl acetate extracts were
poured into separate 100mL labeled beakers. These beakers containing the extracts were left
uncovered in a designated corner of the fume hood to evaporate for 24 to 72 hours. The agar
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that remained in the first set of beakers was then treated with another 50mL of either
methanol or ethyl acetate, covered, and left to soak for another 24 hours. After this, the
extracts were combined with the previous extracts in their respective beakers and left for 1-4
days in the fume hood for complete evaporation (Figure 1a). Each of the extracts was then
redissolved in 1.5mL of 100% methanol and transferred to a 1.5mL eppendorf tube and stored
at 4°C until use (Figure 1b).

Figure 1: a. Extraction from agar cultures (adapted from Borisova 2011) b. Resuspension of
extract in methanol and sterilization in preparation for the MTT assay.

Cancer Cell Lines
The cell lines used in these studies were MCF7, a Human Breast Adenocarcinoma (cat #
HTB-22, ATCC, Manassas, Virginia) and LM929. The MCF7 were the experimental cell line that
was originally harvested from the mammary gland of a 69 year old Caucasian female. The
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LM929 cells are from a macrophage cell line and were generously donated by Stephen Chapes
(Kansas State University, Manhattan, Kansas). The LM929 cells represent healthy tissue and
were selected as a cellular control.
Cell Preparation and Treatment
The LM929 cell line was maintained by culture in Dulbecco's Modified Eagle Medium
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS). No antibiotics were added to the
culture media. Passage of these cells was executed using the following procedure. Cellular
debris and used media was suctioned out of the 25cm3 culture flask (Fisher Sci, Pittsburgh,
Pennsylvania) and 2 ml of Trypsin (1X) was added to the flask. LM929 cells are adherent cells
and form cellular adhesions that allow them to attach to the bottom of the flask. The addition
of Trypsin promotes the breaking of the cellular adhesions and causes release of the cells into
the solution in order for cell harvesting and transfer. The Trypsin was left in the flask with the
LM929 cells for 3-5 minutes while the flask remained in the sterile hood. Cells were then rinsed
from the flask using 4 ml of DMEM supplemented with 10% FBS. The collected suspension with
a total volume of 6 ml (cells, 2 ml Trypsin, 4 ml DMEM media) was transferred to a 15 ml
centrifuge tube (Fisher Sci, Pittsburgh, Pennsylvania) and centrifuged (1200 rpm, 5 min, 6°C).
After centrifugation, the supernatant was removed and disposed of. The cellular pellet was
resuspended in 6 ml of DMEM supplemented with 10% FBS. A fraction of this suspension was
added to the culture flask and brought up to a final volume of 6 ml with DMEM supplemented
with 10% FBS and returned to the incubator (37°C, 5% CO2).
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An alternate procedure was used to maintain the MCF7 cell line. DMEM supplemented
with 10% FBS was used in the same quantities as described with the LM929 cell line. MCF7 cells
were collected by suctioning out the media in the 25 cm3 flask and adding 2 ml of Trypsin. The
flask was then placed in the incubator (37°C, 5% CO2) for 25-30 minutes. MCF7 cells form cell
adhesions to the bottom of the flask and to their neighboring cells. These adhesions make the
cells appear very clumpy and, when compared to those of the LM929 are stronger and cause
the cell to adhere more strongly to the flask and its neighboring cells. Therefore, a longer
incubation period with the trypsin is needed to cause the MCF7 cells to release from the
bottom of the flask and separate from their neighboring cells. After incubation the cells in the
flask were rinsed with 4 ml of DMEM supplemented with 10% FBS and the cell suspension
(cells, 2 ml Trypsin, 4 ml DMEM media) collected and transferred to a 15 ml centrifuge tube
(Fisher Sci. Pittsburgh, Pennsylvania). The tube was centrifuged at 450 rpm for 5 minutes at 6°C.
The supernatant was then removed and the cell pellet was resuspended in 6 ml of DMEM
supplemented with 10% FBS. A fraction of this suspension was added to the 25 cm3 culture
flask and brought up to a final volume of 6 ml with DMEM supplemented with 10% FBS and
returned to the incubator (37°C, 5% CO2).
MTT Assay
An MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is a
colorimetric assay that is used to examine cell viability. This assay is based on a cellular
reduction reaction that takes place in the mitochondria of living cells (Figure 2). MTT is a
positively charged tetrazolium salt that is a pale yellow color. It is taken up by the cell and
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enters into the mitochondrion. Within the mitochondrion MTT is acted on by the enzyme
mitochondrial reductase and converted to formazan, a purple colored crystal. Once the MTT is
converted to formazan crystals, it cannot pass through or be transported across the plasma
membrane and begins to accumulate within the cell. After a fixed incubation period, a
solubilization buffer is added. This buffer lyses the cells and dissolves any formazan crystals that
were formed. If there were living cells in the test wells, there would be mitochondrial reductase
activity promoting MTT conversion to formazan crystals. In this case the addition of the
solubilization buffer would result in the solution in the test well turning a purple color. If there
were no living cells present in the test well, there would be no active mitochondrial reductase
enzyme to convert MTT to formazan crystals. This would result in a test well that has no purple
color. Absorbencies for each of the test wells are measured with a plate reader. Varying shades
of purple color that are measured in each well are proportional to the number of living cells in
that well. This means that lighter purple color indicates fewer living cells and dark purple color
indicates more living cells. The MTT assay is used as a quantitative method to allow cell viability
to be determined through a colormetric, or color changing reaction which is directly
proportional to the activity of the mitochondrion.

Figure 2: Conversion of MTT to formazan in the mitochondria (Stockert et al, 2012)
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In preparation for the MTT assay cells were collected from a 25 cm3 flask of the
appropriate cell line and transferred to a Corning 75 cm3 flask (Fisher Sci, Pittsburgh,
Pennsylvania) in order to increase cell yield. These larger flasks were maintained using the same
procedures as mentioned above corresponding to their cell line. Once the fraction of cells was
added to the 75 cm3 flask, DMEM supplemented with 10% FBS was added to a final volume of
15 ml. Cells were grown until confluency was achieved before an assay was performed.
Cells from the MCF7 and LM929 cell lines were collected from confluent 75 cm3 flasks
using the procedures mentioned above with the only modifications being the use of 5mL of
trypsin in order to break cell adhesions and 6mL of DMEM supplemented with 10% FBS to rinse
the flask. The incubation times and centrifugation parameters were all kept consistent for all
flasks of each cell line. After cells were centrifuged the supernatant was removed and the cell
pellet was resuspended with 10mL of DMEM supplemented with 10% FBS. A cell count was
then preformed using a hemocytometer and a new cell suspension of 5 x 104 cells/mL was
made. This new cell suspension was used to seed all the wells of the 96 well cell culture plates
used for the MTT assay so that there were 5 x 104 cells per well.
Each well of the 96 well cell culture plate was seeded with 100µl of DMEM
supplemented with 10% FBS. An additional 70µl of DMEM supplemented with 10% FBS was
added to the first 3 wells of each of the rows corresponding to a sample. Next, 30µl of filter
sterilized sample compounds was added to the first 3 wells of a row. The compounds were then
serially diluted in triplicate across one row of the cell culture plate by removing 100µl from each
of the first 3 wells and pipetting it into the following triplicate of wells in that row using a
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multichannel pipette for accuracy. The dilution was carried out through the last triplicate of the
row and the remaining 100µl from the last 3 wells after dilution was discarded. 100µl of the 5 x
104 cell dilution was then added to each of the wells. The final volume of each well was 200µl
(Figure 3). Each set of assay cell culture plates was run with a serial dilution in triplicate of HCl
across 2 rows in order to establish a percent killing curve. Additional controls run across one
row of wells in triplicate included cells in media only control, a 15% methanol control, a 15%
blank methanol RM agar plate extraction control and a 15% blank ethyl actetate-methanol RM
agar plate extraction control.

Figure 3: MTT assay cell culture plate set up
All cell culture plates were placed in the incubator (37°C, 5% CO2) for 72 hours. These
conditions promoted cell growth and proliferation while giving the cells enough time to
propagate so that any effect the compound had on cell growth could be observed. After this
incubation period, the plates were removed from the incubator and 20µl of MTT reagent was
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added to each well. The plates were then placed back into the incubator for an additional 4
hours to allow the MTT to be taken up by any living cells and converted to formazan crystals by
the enzyme mitochondrial reductase. After this incubation period, the cell culture plates were
removed from the incubator and the growth media in each well was suctioned off and
discarded, taking care not to suction off the cells that were still adherent to the bottom of the
wells. Then, 200µl of Iso-PBS, a solubilization buffer, was added to each of the wells in order to
dissolve any formazan crystals that were present in the wells. Each plate was then wrapped
tightly with plastic wrap and left overnight on the bench top at room temperature and read by
the plate reader the following day. This was to ensure that the Iso-PBS solubilization buffer had
sufficient time to dissolve all the formazan crystals that were formed in order to get an accurate
absorbency reading of each test well.
The cell culture plates were read using at plate reader at 620nm. After the plates were
read and the absorbencies recorded, the average absorbency of each triplicate was calculated.
The percent kill (% kill) and percent inhibition of each of the compounds and controls was
determined by comparing the average absorbency of the sample triplicate to the average
absorbency of each of the controls using the following formulas where Max = the acid control,
Ctl = the media control, A = mean absorbance value of treated wells, and B = mean absorbency
values of the control wells.
% Kill = (Exp – Ctl)/(Max-Ctl) x 100
% Inhibition = (1-A/B) x 100%
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The absorbencies of each of the compounds were evaluated using a two-way ANOVA.
Being that each treatment was done in triplicate it was important to select a test that
considered the spread of the data within each treatment and was able to compare the means
of each treatment. The two-way ANOVA statistical test was chosen because it is a more robust
statistical analysis that is able to determine if there is a statistically significant difference
between the means of the treatments relative to the spread of the observations for each
concentration treatment.
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CHAPTER 3
RESULTS
MTT Assay Analysis
A two-way ANOVA was performed for each one of the compound extracts in order to
assess if there was a significant variation between the mean absorbency reading at 620nm of
the triplicates undergoing treatment and the means of the control triplicates. Each of the
compound extracts was compared to a media control and to a methanol control that was
conducted on the same set of assay plates in order to control for factors such as barometric
pressure, humidity, and cell passage number. The methanol compound extracts were then
compared to a blank-methanol control while the ethyl acetate extracts were compared to a
blank-ethyl acetate methanol control. The hydrochloric acid control (HCl) was not used to
compare the treatments because it demonstrated an all or nothing cell survival response and a
cell survival curve could not be determined.
A nonsignificant two-way ANOVA, meaning the p-value for interaction is above the level
of significance (α > 0.05), indicates that the effect of concentration is similar for the treatment
and the control. The interaction plot for a compound and a control that was not significant
would show the control and the treatment with the compound extract behaving in a similar
pattern with respect to concentration (Figure 4).
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Figure 4: Non-significant interaction plot with LM929 cells between the media control and
strain CODET15 meth. Both the media control and CODET15 meth show a decrease in the
triplicate mean with an increase in concentration.

A significant two-way ANOVA, meaning the p-value for interaction is below the level of
significance (α < 0.05), indicates that the effect of concentration is different for the treatment
and the control. The interaction plot for a compound and a control that was significant would
show the control and the compound extract behaving differently with respect to the
concentration (Figure 5).
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Figure 5: Significant interaction plot with LM929 cells between the media control and strain
MTM3015 meth. Both the media control and MTM3015 meth show a decrease in the triplicate
mean with an increase in concentration, however MTM3015 showed a significant decrease in
mean absorbency at the 7.5% and 15% concentrations.
MCF7 MTT Assays
All 3 controls had a significant interaction p-values when compared to the media control
(Figure 6). As the concentration of the control treatment increased, the absorbency decreased.
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Figure 6: The interaction plot for MCF7 cells assayed on plates 1-5. The methanol control,
BLANK methanol control and the BLANK EA-M controls showed a significant interaction
(p < .05).

In comparing all 60 compound extracts, as well as the methanol, blank-methanol, and
blank ethyl acetate-methanol controls to the media control in the assays using MCF7 cells, it
was seen that all 60 showed an interaction p-value that was significant (α < 0.05). This means
that the addition of each of the compound extracts to their respective wells caused there to be
a significant difference in the mean absorbency of the treated triplicates when compared to the
mean absorbencies of the media control triplicates. In looking at the individual interaction plots
it was seen that the biggest variation in mean absorbency reading was seen at the 15%
concentration and the 7.5% concentration (Figure 7). This indicates that at higher
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concentrations of compound extract, there were fewer living cells as indicated by the low
absorbency reading.

Figure 7: The interaction plot for strain KCHXC3 with MCF7 cells showing a significant
interaction when compared to the media and agar controls (p < .05).

In comparing 60 compound extracts to the methanol control, 36 of them showed an
interaction p-value that was significant. Eighteen of these compounds extracts were methanol
and the other 18 where ethyl acetate-methanol compound extracts (Table 4).

39

Table 4: a. Methanol compound extracts that showed significant interaction p-values
when compared to the methanol control. b. Ethyl Acetate-Methanol compound extracts
that showed significant interaction p-values when compared to the methanol control.
a.

b.

WLDET3 meth

AZM3R1 meth

WDM3P2 meth

DSM301 meth

ACM3W7 meth

CODET15 meth

MTM3015 meth

NPDE011 meth

ACM3W7 meth

WFIEW1 meth

MTM309a meth

WDM310A meth

SCM3011 meth

WDM318 meth

WFDEM6 meth

CBRMT7 meth

ACM3W5 meth

WDM310a meth

NFDEM13 EA-M

MTM3W12.1a EA-M

WDM3P2 EA-M

DSM301 EA-M

BTHXC10 EA-M

AZM3R1 EA-M

WFDEM6 EA-M

NPDE011 EA-M

ACM3W7 EA-M

WLDE08 EA-M

MTM309a EA-M

WDM310A EA-M

ACM3W7 EA-M

WFIEW1 EA-M

WDM318 EA-M

ACM3C1 EA-M

WFDEM6 EA-M

MTM3T20 EA-M

The blank-methanol control was used to account for any component in the agar that
may have an effect on the proliferation of the MCF7 breast cancer cells. The blank-methanol
rich media (RM) plates did not contain bacteria and were extracted using the same methods as
the RM plates with bacteria. There were 11 methanol compound extracts that had a significant
p-value when compared to the blank methanol control (Table 5).
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Table 5. Compounds extracts that showed a significant interaction p-value when
compared in a two-way ANOVA to the blank-methanol control.
WFDE08 meth
CODE08 meth
WLDET3 meth
MTM3W5.2 meth
KCHXC3 meth 1
MTM3T17 meth

NPDEM14 meth
WFDEM2 meth
CBRMT10 meth
NFDEM13 meth
KCHXC3 meth 2

For the bacterial strains that were extracted using ethyl acetate and methanol, a blank
ethyl acetate-methanol (EA-M) control was used. All the strains that were extracted with ethyl
acetate and reconstituted in methanol were compared to this control in order to assess if there
was a component of the agar that was causing a variation in the absorbency reading or the
variation was caused by something in the compound extract. There were 24 ethyl acetatemethanol compounds extracts that showed significant interaction p-values when compared to
the blank EA-M control (Table 6).
Table 6: Compound extracts that showed significant interaction p-values when compared in a
two-way ANOVA to the blank EA-M control.
WFDE08 EA-M
MTDE09 EA-M
MTM306 EA-M
NFDEM13 EA-M
MTM3T17 EA-M
SCM3011 EA-M

NPDEM14 EA-M
WFDEM2 EA-M
MTM3W5.2 EA-M
KCHXC3 washed EA-M
BTHXC8 EA-M
ACM3W7 EA-M

NPDE012 EA-M
WLDET3 EA-M
NP3T8.1 EA-M
KCHXC3 EA-M 1
CODET15 EA-M
WDM318 EA-M

CODE08 EA-M
CBRMT10 EA-M
APDE02 EA-M
KCHXC3 EA-M 2
WFIEW1 EA-M

MTM3T20 EA-M

All compound extracts that showed interaction with any of the controls were noted and
used for comparison to the interaction with LM929 cells (Table 7).
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Table 7: Summary of all the extracts that showed significant interaction p-values in a two way
ANOVA when compared to a methanol, blank methanol, and blank ethyl acetate-methanol
control for the MTT assays conducted with MCF7 cells.
Strain

Methanol

WFDE08 meth
WFDE08 EA-M
NPDEM14 meth
NPDEM14 EA-M
NPDE012 EA-M
CODE08 meth
CODE08 EA-M
MTDE09 EA-M
WFDEM2 meth
WFDEM2 EA-M
WLDET3 meth
WLDET3 EA-M
CBRMT10 meth
CBRMT10 EA-M
MTM306 EA-M
MTM3W5.2 meth
MTM3W5.2 EA-M
NP3T8.1 EA-M
APDE02 EA-M
NFDEM13 meth
NFDEM13 EA-M

no
no
no
no
no
no
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
yes
no
no
no
no
no
no
no
yes
no
yes
yes

KCHXC3 washed EA-M

KCHXC3 meth 1
KCHXC3 EA-M 1
KCHXC3 meth 2
KCHXC3 EA-M 2
MTM3T17 meth
MTM3T17 EA-M
MTM3W12.1a EA-M

BTHXC8 EA-M
DSM301 meth
DSM301 EA-M

Blank
Meth
yes

Blank
EA-M
yes

yes
yes
yes
yes
yes
yes

Strain

Methanol

AZM3R1 meth
AZM3R1 EA-M
NPDE011 meth
NPDE011 EA-M
CODET15 meth
CODET15 EA-M
WLDE08 EA-M

yes
yes
yes
yes
yes
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

WDM310A meth
WDM310A EA-M

yes

BTHXC10 EA-M
WDM3P2 meth
WDM3P2 EA-M
ACM3C1 EA-M
WFIEW1 meth
WFIEW1 EA-M
WFDEM6 meth
WFDEM6 EA-M
SCM3011 meth
SCM3011 EA-M
MTM3015 meth
WFDEM6 EA-M
ACM3W7 meth
ACM3W7 EA-M
MTM309a meth

yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes

MTM309a EA-M

yes

ACM3W7 meth
ACM3W7 EA-M
WDM318 meth
WDM318 EA-M

yes
yes
yes
no
yes

MTM3T20 EA-M

CBRMT7 meth
ACM3W5 meth
WDM310a meth

no
no
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Blank
Meth
no

Blank
EA-M
no

no
no
no
yes
no
no
no
no
no
no
no
no
yes
no
no
no
yes
no
no
no
no
no
no
no
yes
no
yes
yes
no
no
no

LM929 MTT Assays
It is important to use the LM929 cell line in this investigation. This cell line acts as a
healthy cell control. In the scope of cancer treatment, the ideal goal is to eradicate the
cancerous cells while leaving the healthy cells unharmed. While it is important to assay for the
effect of potential compounds against cancerous cells, it is also important that the compounds
be assayed with healthy cells to assess their effects. A strong candidate for further investigation
would be a compound that showed significant interaction when assayed with MCF7 cells but
nonsignificant interaction when assayed with LM929 cells.
All 60 compound extracts, as well as the blank-methanol and blank-ethyl acetatemethanol controls, were assayed using LM929 cells and compared in a two-way ANOVA to
media and methanol controls. When compared to the media control, the methanol control did
not show a significant interaction p-value; however, both the blank-methanol and blank EA-M
controls did show a significant interaction p-value (Figure 8). Again a significant P-value
indicates that that the test component in the well is behaving differently than the control to
which it is being compared.
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Figure 8: The interaction plot for LM929 cells assayed on plates 1-4. The BLANK methanol
control and the BLANK EA-M controls showed a significant interaction while the methanol
control did not show a significant interaction p-value.
There were 16 methanol compound extracts and 21 EA-M compound extracts that
showed significant interaction p-values in a two-way ANOVA when compared to the media
control (Table 8).
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Table 8: a. Methanol compound extracts that showed significant interaction p-values when
compared to the media control in a two-way ANOVA. b. EA-M compound extracts that showed
significant interaction p-values when compared to the media control in a two-way ANOVA.
a.

CBRMT10 meth
ACM3C8 meth
BTHXC2 meth
MTM304 meth
MTM3W12.1a meth
DSM301 meth
MTM3015 meth
ACM3W7 meth

NP3T8.1 meth
ACM3W1 meth
MTM3010 meth
CODET15 meth
KCHXC3 washed meth
AZM3R1 meth
WFDEM6 meth
MTM309a meth

KCHXC3 EAM
AZM306 EAM
ACM3C8 EAM
BTHXC8 EAM
MTM3010 EAM
EMHX01 EAM
MTM3W13 EAM
KCHXC3 washed EAM
AZM3R1 EAM
MTM3015 EAM
MTM304 EAM

MTM3W12.1a EAM
BTHXC10 EAM
ACM3W1 EAM
BTHXC2 EAM
CODET5 EAM
KCHXC3 EAM 2
NPM311 EAM
DSM301 EAM
NPDE011 EAM
MTM309a EAM

b.

There were 8 methanol compound extracts and 7 EA-M compound extracts that had
significant interaction p-values against the methanol control (Table 9).
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Table 9: a. Methanol compound extracts that showed significant interaction p-values
when compared with a methanol control in a two-way ANOVA. b. EA-M compound
extracts that showed significant interaction p-values when compared with a methanol
control in a two-way ANOVA.
a.

b.

CBRMT10 meth

ACM3C8 meth

MTM3010 meth

MTM304 meth

CODET15 meth

MTM3T17 meth

MTM3W12.1a meth

KCHXC3 washed meth

NFDEM13 EAM

KCHXC3 EAM

AZM306 EAM

BTHXC2 EAM

MTM3010 EAM

EMHX01 EAM

KCHXC3 washed EAM

A blank-methanol control was used in the two-way ANOVA analysis for those compound
extracts that were extracted with methanol. There were 23 methanol compound extracts that
showed significant interaction p-value (Table 10a). A blank EA-M control was used in the twoway ANOVA analysis for those compound extracts that were extracted with ethyl acetate and
reconstituted in methanol. There were 23 EA-M compound extracts that showed significant
interaction p-values (Table 10b).
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Table 10: a. Methanol compound extracts that showed significant interaction p-values when
compared to a blank methanol control. b. Ethyl acetate-methanol compound extracts that
showed significant interaction p-values when compared to a blank EA-M control.
a.

b.

WFDE08 meth
WFDEM2 meth
MTM3W12.1 a meth
MTM3010 meth
KCHXC3 washed meth
WLDE08 meth
SCM3011 meth
WDM310a meth

NPDEM14 meth
MTM306 meth
ACM3C8 meth
CODET15 meth
KCHXC3 meth 1
ACM3C1 meth
ACM3W7 meth
MTDDE09 meth

MTDE09 meth
MTM3W5.2 meth
MTM310 meth
MTM3T17 meth
CODET15 meth
WFIEW1 meth
NPM311 meth

WFDE08 EAM
NFDEM13 EAM
CBM3T2 EAM
BTHXC2 EAM
NPM311 EAM
CODET15 EAM
ACM3C1 EAM
ACM3W7 EAM

MTDE09 EAM
KCHXC3 EAM
CBMT7 EAM
MTM3010 EAM
KCHXC3 washed EAM
WLDE08 EAM
WFDEM6 EAM
WDM318 EAM

MTM306 EAM
AZM306 EAM
MTM310 EAM
KCHXC3 EAM 2
KCHXC3 EA- 1
WDM3P2 EAM
SCM3011 EAM

A summary of all the compound extracts and their activity with LM929 cells were noted
to be used for a comparison (Table 11).
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Table 11: Summary of all the extracts that showed significant interaction p-values in a two-way
ANOVA when compared to a media, methanol, blank methanol, and blank ethyl acetatemethanol control for the MTT assays conducted with LM929 cells.
Strain

Media

Methanol

Blank
Meth
yes

Blank
EA-M

WFDE08 meth
WFDE08 EA-M
NPDEM14 meth
MTDE09 meth
MTDE09 EA-M
WFDEM2 meth
CBRMT10 meth
MTM306 meth
MTM306 EA-M
MTM3W5.2
meth
NP3T8.1 meth
NFDEM13 EA-M
KCHXC3 EA-M
MTM3W12.1 a
meth
MTM3W12.1a
EA-M
AZM306 EA-M
BTHXC10 EA-M
CBM3T2 EA-M
ACM3C8 meth
ACM3C8 EA-M
ACM3W1 meth
ACM3W1 EA-M
BTHXC8 EA-M
CBMT7 EA-M
MTM310 meth
MTM310 EA-M
BTHXC2 meth
BTHXC2 EA-M
MTM3010 meth
MTM3010 EA-M
MTM304 meth
CODET15 meth
CODET5 EA-M
EMHX01 EA-M
KCHXC3 EA-M 2
MTM3T17 meth
MTM3W13 EAM

no
no
no
no
no
no
yes
no
no
no

no
no
no
no
no
no
yes
no
no
no

yes
no
yes
no

no
yes
yes
no

yes

no

no

yes
yes
no
yes
yes
yes
yes
yes
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
yes

yes
no
no
yes
no
no
no
no
no
no
no
no
yes
yes
yes
no
yes
no
yes
no
yes
no

yes
no
yes

yes
yes
yes
yes
yes
no
yes
yes
yes
no
yes
yes
yes

yes
no
no
no
no
yes
yes
yes
no
yes
yes
yes
no
yes
no
no
yes
yes
no
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Strain

Media

Methanol

Blank
Meth

NPM311 EA-M
MTM3W12.1a
meth
KCHXC3 washed
meth
KCHXC3 washed
EA-M
KCHXC3 meth 1
KCHXC3 EA-M 1
DSM301 meth
DSM301 EA-M
AZM3R1 meth
AZM3R1 EA-M
NPDE011 EA-M
CODET15 meth
CODET15 EA-M
WLDE08 meth
WLDE08 EA-M
WDM3P2 EA-M
ACM3C1 meth
ACM3C1 EA-M
WFIEW1 meth
WFDEM6 EA-M
SCM3011 meth
SCM3011 EA-M
MTM3015 meth
MTM3015 EA-M
WFDEM6 meth
ACM3W7 meth
MTM309a meth
MTM309a EA-M
ACM3W7 meth
ACM3W7 EA-M
WDM318 EA-M
MTM304 EA-M
NPM311 meth
WDM310a
meth
WDEW3 meth
MTDDE09 meth

yes
yes

no
yes

yes

yes

yes

yes

yes

yes

no
no
yes
yes
yes
yes
yes
no
no
no
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
no
no
no
yes
no
no

no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no

yes

no
no

no
no

no
yes

Blank
EA-M
yes

yes

yes
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
no
no
no
no
no
yes
yes
yes
no
yes
yes

Activity Comparison in the MCF7 and LM929 Cell Lines
An ideal candidate for further investigation would be a compound extract that showed
growth inhibition or killing activity when assayed with the MCF7 cells but no activity when
assayed with the LM929 cells. Evaluation based on the compound extract activity when
compared to either the blank methanol or blank ethyl acetate-methanol control is used to
evaluate potential strains of Rhodococcus that warrant further evaluation as to their compound
properties in the cancer treatment setting. These both are reliable controls because they have
been subject to the extraction procedure and they allow the bacterial strain compounds to be
an isolated variable for testing.
Among the 60 Rhodococcus strains that were assayed and the 120 compound extracts,
18 compound extracts showed significant interaction p-values when compared to either the
blank methanol control or the blank ethyl acetate-methanol control in the MTT assay with
MCF7 cells (Table 12). These same compound extracts showed nonsignificant interaction pvalues when compared to the blank methanol and blank ethyl acetate-methanol controls in the
MTT assay with LM929 cells.
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Table 12: All of the compound extracts that showed significant interaction p-values in a
two-way ANOVA against the blank methanol or blank ethyl acetate methanol controls in a
MCF7 MTT assay but showed no significant interaction p-values in a two-way ANOVA against
these same controls in a LM929 MTT assay.
NPDEM14 EA-M

NPDE012 EA-M

CODE08 meth

CODE08 EA-M

WFDEM2 EA-M

WLDET3 meth

WLDET3 EA-M

CBRMT10 meth

CBRMT10 EA-M

MTM3W5.2 EA-M

NP3T8.1 EA-M

APDE02 EA-M

NFDEM13 meth

KCHXC3 meth 2

MTM3T17 EA-M

BTHXC8 EA-M

WFIEw1 EA-M

MTM3T20 EA-M

Washed RM Agar Plates and Their Effect on Activity
Washed rich media (RM) agar plates refers to removing the growing bacteria from the
surface of the plate before extraction. Removal of the bacteria leaves only the compounds that
were released in the agar to be extracted. This was done with the KCHXC3 Rhodococcus strain
in order to see if there was a difference in the activity of the compound extract when the
bacteria were extracted along with the agar and when the agar was extracted alone.
Methanol compound extracts were compared for the MCF7 and LM929 MTT assays
using a two-way ANOVA (Table 12). The strain KCHXC3 was extracted on 2 different days in
order to observe if there was a consistency in the activity of the compound extract. In looking
at the MCF7 MTT assay results, it is seen that there is consistency with the activity of both the
KCHXC3 methanol 1 and KCHXC3 methanol 2 compound extracts with both of them showing a
significant interaction p-value when compared to the media and blank methanol controls but
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no significant interaction when compared to the methanol control (Table 13a). When
comparing this to the activity of KCHXC3 washed methanol compound extract there was a
difference in activity when looking at the blank methanol control. This result could indicate that
there is something being produced and not excreted by the bacteria that causes an inhibitory
growth effect.
In the MTT assays with the LM929 cells, there was a difference in activity among the 2
KCHXC3 compound extracts (Table 13b). The difference is with their activity when compared to
the blank methanol control. The KCHXC3 methanol 1 compound extract showed a significant
interaction p-value when compared to the blank methanol control while the KCHXC3 methanol
2 compound extract did not show a significant p-value. The activity of the KCHXC3 washed
methanol compound extract was different from both of the controls and showed a significant
interaction p-value when compared to each one of the controls.

Table 13: a. Methanol compound extracts and their activity in a MTT assay with MCF7 against a
media, methanol, and blank methanol control separately. b. Methanol compound extracts and
their activity in a MTT assay with LM929 cells against a media, methanol, and blank methanol
control. A yes result indicates that the compound extract had a significant interaction p-value
when compared to the control individually.
Strain
KCHXC3
washed
meth
KCHXC3
meth 1
KCHXC3
meth 2

Methanol Blank Meth

Strain

Media

Methanol

Blank Meth

yes

no

no

KCHXC3
washed meth

yes

yes

yes

yes

no

yes

no

no

yes

yes

no

yes

KCHXC3 meth
1
KCHXC3 meth
2

no

no

no

Media

a. MCF7 MTT Assay Activity

b. LM929 MTT Activity
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The ethyl acetate-methanol compound extracts for the strain KCHXC3 were also
compared. With the MCF7 MTT assay, both the KCHXC3 compound extracts showed the same
activity with significant interact p-values compared to the media and blank EA-M controls. The
KCHXC3 washed EA-M compound extract also demonstrated the same activity pattern with
significant interaction p-values compared to the media and blank methanol controls and no
significance when compared to the methanol control (Table 14a).
There was a difference of activity in the 2 KCHXC3 compound extracts against the
LM929 cells. The difference is with the media control. KCHXC3 EA-M 1 compound extract did
not show a significant interaction p-value when compared to the media control while KCHXC3
EA-M 2 compound extract did show a significant interaction p-value (Table 14b). Both of the
KCHXC3 EA-M compound extracts showed a different activity pattern when compared to the
KCHXC3 washed EA-M extract. In this case the washed extracted showed a significant p-value
when compared to all 3 controls.
Table 14: a. Ethyl acetate-methanol compound extracts and their activity in a MTT assay with
LM929 against a media, methanol, and blank methanol control separately. b. Ethyl acetatemethanol compound extracts and their activity in a MTT assay with LM929 cells against a
media, methanol, and blank methanol control. A yes result indicates that the compound extract
had a significant interaction p-value when compared to the control individually.
Strain

Media

Methanol

Blank EA-M

Strain

Media

Methanol

Blank EA-M

KCHXC3
washed
EA-M
KCHXC3
EA-M 1
KCHXC3
EA-M 2

yes

no

yes

yes

yes

yes

yes

no

yes

no

no

yes

yes

no

yes

KCHXC3
washed
EA-M
KCHXC3
EA-M 1
KCHXC3
EA-M 2

yes

no

yes

a. MCF7 MTT Assay Activity

b. LM929 MTT Assay Activity
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Extraction Using a Minimal Media
For the MTT assays conducted with MCF7 cells, the blank methanol and blank EA-M
extraction showed significant interaction p-values when compared to the media control in both
the MTT assays with MCF7 and LM929 cells. These blank controls go through the same
extraction process with the only difference being that they are not seeded with bacteria. This
result indicates that there could be some component of the RM agar that is causing there to be
an effect on the cells. Fiss minimal agar was used to assess if there was a component in the agar
that was causing the activity with the MCF7 and LM929 cells in the MTT assays. Minimal media
contains the essential components for bacteria to grow. Two separate Fiss agar plates from the
same batch of media were extracted in order to test the activity against the 3 controls and the
consistency of the activity. It was seen that there was no consistency in the pattern of activity
to the controls with either the blank Fiss methanol or blank Fiss EA-M compound extracts
(Table 15). In looking at the Blank Fiss methanol plates 1 and 2, it is seen that against the media
control and the blank methanol control, plate 1 showed significance and plate 2 did not. An
inconsistency in activity was also seen in the Blank Fiss ethyl acetate-methanol plates 1 and 2.
In this case, plate 1 did not show significance against the media and Blank ethyl acetatemethanol control while plate 2 did show significance against these controls.
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Table 15: MTT assay activity results based on a two-way ANOVA against a
media, methanol, blank methanol, and blank EA-M controls
Strain

Media

Methanol

Blank meth

Blank EA-M

Blank Fiss
meth 1
Blank Fiss
meth 2
Blank Fiss
EA-M 1
Blank Fiss
EA-M 2

yes

no

yes

n/a

no

no

no

n/a

no

no

n/a

No

yes

no

n/a

yes
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CHAPTER 4
DISCUSSION
The bacterium Rhodococcus is best known for its industrial success in the area of fossil
fuel desulfurization. Following the sequencing of its genome in 2006, it was found that it
contains 7 polyketide synthases and 24 nonribosomal peptide synthases (McLeod et al. 2006).
The presence of these enzymes and the knowledge that they have been shown to produce
antibiotics in other closely related bacteria has sparked interest in exploring Rhodococcus as a
producer of inhibitory compounds.
Other related bacteria in the order Actinomycetales have produced compounds that
have been used, or have influenced synthetic compounds that have been used in cancer
treatment. Currently 9 genera in the order Actinomycetales have been studied and proved
successful in producing drug-like products. The distribution of identified drug producing families
on the bacterial phylogenetic tree suggest that the drug producing families tend to cluster. The
family Nocardiaceae, which includes Rhodococcus, is related to the drug productive family
Corynebacteriaceae that emerged in 2000 as a bioprospecting target (Zhu et al. 2011).
Investigation into other related bacterial families could potentially lead to the discovery of
useful bioactive compounds.
Based on these initial findings and previous success in this lab concerning the discovery
of compounds that show effective bacterial growth inhibition, we hypothesized that
Rhodococcus would be a bioprospecting target for inhibitory compounds against MCF7 breast
cancer cells. Upon agar extraction screening using methanol and ethyl acetate, 18 compound
extracts from 15 strains of Rhodococcus have shown significant activity against MCF7 breast
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cancer cells while demonstrating no significant activity against the healthy cell control line of
LM929 cells.
The results of this initial screening of these strains of Rhodococcus show promise in
further investigation of this genus; however, a more in-depth investigation is necessary to
determine the widespread potential of these compounds in the cancer treatment setting. It was
seen that the blank methanol and blank ethyl acetate-methanol controls show significance
when compared to the media control in both the MTT assays with MCF7 cells and LM929 cells.
This indicates that there could be some component in the rich media agar that is causing this
response. When the fIss media agar was tested, it was seen that each 1 of the 2 fiss agar
extracts showed a different activity pattern. Further testing with this agar is suggested to
confirm activity. If it shows no significant activity when compared to the media control, it would
be a good candidate to grow and extract bacteria. If this is not the case, the use of another agar
or agarose that does not have an effect on the growth of the cells would be an ideal choice.
Another possibility for growth media is nutrient broth. Allowing the bacteria to grow in
liquid media with porous resin instead of on a solid surface could cause the production of these
effective compounds. Changing from a solid surface to a liquid media form does have the
potential to change bacteria expression and the compounds that the bacteria produce. This
change in expression may be due to quorum sensing, a signaling system in bacteria that
coordinates gene expression based on cell density (Martin et al. 2005). Changing to broth
media could alter the identified activity of the compound extracts and may be a productive
avenue for further bioactive compound production.
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In looking at the dispersion of bioactive compounds there is an imbalance of distribution
among the sets of assay plates. Out of the 5 sets of assay plates conducted for the MTT assays
with MCF7 breast cancer cells, the majority of the significant compound extracts were found in
the first set of plates. Because each of the compound extracts is compared to the 3 controls
that are run on that set of plates it could be that there was an inaccuracy in the controls on the
first set of plates. This would explain almost all of the compounds showing significant
interaction p-values when compared to the blank methanol and blank ethyl acetate-methanol
control. These compounds would need to be run again dispersed on different assay plates to
confirm the positive activity.
The hypothesis for this investigation was that compound extracts from various strains of
Rhodococcus would have some type of activity when grown with MCF7 breast cancer cells.
More specifically we hypothesized that based on previous bioactivity discovered within the
related bacterial families and the production of growth inhibiting compounds against bacteria
from Rhodococcus strains isolated in the lab, there would be some compound or combination
of compounds produced by this genus of bacteria that would have a inhibitory growth effect or
killing effect on MCF7 breast cancer cells. Eighteen compounds that showed significant
interaction p-values when assayed with the MCF7 breast cancer cells were identified. These
compounds were also selected for future prospecting research because they showed a lack of
activity against the LM929 healthy cell line. In this investigation we reject our null hypothesis
that a compound produced by Rhodococcus does not cause an effect against MCF7 breast
cancer cells.
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Future Direction of This Research
The 18 compound extracts that showed significant interaction (p < 0.05) when assayed
with MCF7 cells and nonsignificant interaction p-values when assayed with LM929 cells require
further investigation. The 15 strains of Rhodococcus that have shown activity represent
potential leads for bioactivity. Purification and identification of the composition of these
identified compound extracts could provide information about the type of compound or
combination of compounds that are having an effect on the MCF7 cancer cells. Further
expansion of these strains of bacteria that show activity can be done with the use of other
growth media and cancer cell lines to see if they have an inhibitory or killing effect.
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